HRP20200439T1 - Onkolitički adenovirus koji kodira protein b7 - Google Patents
Onkolitički adenovirus koji kodira protein b7 Download PDFInfo
- Publication number
- HRP20200439T1 HRP20200439T1 HRP20200439TT HRP20200439T HRP20200439T1 HR P20200439 T1 HRP20200439 T1 HR P20200439T1 HR P20200439T T HRP20200439T T HR P20200439TT HR P20200439 T HRP20200439 T HR P20200439T HR P20200439 T1 HRP20200439 T1 HR P20200439T1
- Authority
- HR
- Croatia
- Prior art keywords
- replication
- competent oncolytic
- oncolytic virus
- virus according
- transgene
- Prior art date
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims 8
- 108090000623 proteins and genes Proteins 0.000 title claims 5
- 230000000174 oncolytic effect Effects 0.000 title claims 3
- 102000004169 proteins and genes Human genes 0.000 title claims 3
- 244000309459 oncolytic virus Species 0.000 claims 17
- 108700019146 Transgenes Proteins 0.000 claims 12
- 241000700605 Viruses Species 0.000 claims 6
- 239000012634 fragment Substances 0.000 claims 5
- -1 B7 -H4 Proteins 0.000 claims 3
- 108010012236 Chemokines Proteins 0.000 claims 3
- 102000019034 Chemokines Human genes 0.000 claims 3
- 102000004127 Cytokines Human genes 0.000 claims 3
- 108090000695 Cytokines Proteins 0.000 claims 3
- 101710132641 Protein B7 Proteins 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000001270 agonistic effect Effects 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000007704 transition Effects 0.000 claims 2
- 102100036842 C-C motif chemokine 19 Human genes 0.000 claims 1
- 102100021943 C-C motif chemokine 2 Human genes 0.000 claims 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 claims 1
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 1
- 102100031092 C-C motif chemokine 3 Human genes 0.000 claims 1
- 101710155856 C-C motif chemokine 3 Proteins 0.000 claims 1
- 102100032367 C-C motif chemokine 5 Human genes 0.000 claims 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 claims 1
- 102100025279 C-X-C motif chemokine 11 Human genes 0.000 claims 1
- 102100025277 C-X-C motif chemokine 13 Human genes 0.000 claims 1
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 claims 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 claims 1
- 108020004414 DNA Proteins 0.000 claims 1
- 102100020715 Fms-related tyrosine kinase 3 ligand protein Human genes 0.000 claims 1
- 101710162577 Fms-related tyrosine kinase 3 ligand protein Proteins 0.000 claims 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims 1
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 claims 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 1
- 101000897480 Homo sapiens C-C motif chemokine 2 Proteins 0.000 claims 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 claims 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 1
- 101000797762 Homo sapiens C-C motif chemokine 5 Proteins 0.000 claims 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 claims 1
- 101000858060 Homo sapiens C-X-C motif chemokine 11 Proteins 0.000 claims 1
- 101000858064 Homo sapiens C-X-C motif chemokine 13 Proteins 0.000 claims 1
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 claims 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 claims 1
- 102100026720 Interferon beta Human genes 0.000 claims 1
- 102100037850 Interferon gamma Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108090000467 Interferon-beta Proteins 0.000 claims 1
- 108010074328 Interferon-gamma Proteins 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000172 Interleukin-15 Proteins 0.000 claims 1
- 108010002350 Interleukin-2 Proteins 0.000 claims 1
- 102000000588 Interleukin-2 Human genes 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 1
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 claims 1
- 230000003042 antagnostic effect Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229950002830 enadenotucirev Drugs 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 230000003612 virological effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/761—Adenovirus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/555—Interferons [IFN]
- C07K14/56—IFN-alpha
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70532—B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10371—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (21)
1. Replikacijski kompetentni onkolitički adenovirus iz skupine B sa selektivnošću za stanice raka, naznačen time što adenovirus sadrži transgen pod kontrolom endogenog virusnog promotora, gdje transgen sadrži slijed DNA koji kodira protein B7,
gdje se navedeni transgen nalazi između mjesta za prepoznavanje prijelaza stop kodon-poliA adenovirusnog gena L5 i mjesta za prepoznavanje prijelaza stop kodon-poliA adenovirusnog gena E4,
gdje je navedeni transgen pod kontrolom endogenog glavnog kasnog promotora.
2. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 1, naznačen time što se protein B7 neovisno bira iz skupine koju čine B7-1, B7-2, B7-DC, B7-H1, B7-H2, B7-H3, B7-H4, B7-H5 i B7-H6.
3. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 2, naznačen time što je protein B7 B7-1.
4. Replikacijski kompetentni onkolitički virus u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je virus kimerni virus.
5. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 4, naznačen time što je okosnica virusa enadenotucirev.
6. Replikacijski kompetentni onkolitički virus u skladu s bilo kojim od patentnih zahtjeva 1 do 5, naznačen time što virus ima formulu (I):
5’ITR-B1-BA-B2-BX-BB-BY-B3-3’ITR (I)
B1 sadrži: E1A, E1B ili E1A-E1B;
BA je E2B-L1-L2-L3-E2A-L4;
B2 je veza ili sadrži E3 ili transgen;
BX je veza ili slijed DNA koji sadrži: restrikcijsko mjesto, jedan ili više transgena ili oboje;
BB sadrži L5;
BY sadrži transgen koji kodira protein B7; i
B3 je veza ili sadrži E4.
7. Replikacijski kompetentni onkolitički virus u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačen time što protein B7 sadrži transmembranski slijed.
8. Replikacijski kompetentni onkolitički virus u skladu s bilo kojim od patentnih zahtjeva 1 do 7, naznačen time što dodatno sadrži drugi transgen.
9. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 8, naznačen time što drugi transgen kodira polipeptid kojeg se bira iz skupine koju čine citokin, kemokin, antagonistička molekula protutijela ili njezin fragment, te agonistička molekula protutijela ili njezin fragment.
10. Replikacijski kompetentni onkolitički virus u skladu s bilo kojim od patentnih zahtjeva 1 do 9, naznačen time što sadrži drugi i treći transgen.
11. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 9 ili 10, naznačen time što drugi ili treći transgen kodira citokin, kojeg se bira iz skupine koju čine IL-2, IFN-α, IFN-β, IFN-γ, ligand Flt3, GM-CSF, IL-15, te IL-12.
12. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 9 to 11, naznačen time što drugi ili treći transgen kodira kemokin, kojeg se bira iz skupine koju čine MIP-1-α, IL-8, CCL5, CCL17, CCL20, CCL22, CXCL9, CXCL10, CXCL11, CXCL13, CXCL12, CCL2, CCL19 i CCL21.
13. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 9 ili 12, naznačen time što kombinaciju citokina i kemokina kodira virus kojeg se bira iz skupine koju čine Mip1α i ligand Flt3, te Mip1α i IFNα.
14. Replikacijski kompetentni onkolitički virus u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što virus kodira molekulu protutijela ili njezin fragment.
15. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 14, naznačen time što molekula protutijela ili fragment molekule protutijela sadrži transmembransku domenu ili GPI sidro, tako da ima oblik usidren u staničnoj membrani.
16. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 14 ili 15, naznačen time što molekula protutijela ili fragment molekule protutijela sadrži domenu za vezanje na protuljudski antigen CD3.
17. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 14 do 16, naznačen time što je molekula protutijela inhibitorska.
18. Replikacijski kompetentni onkolitički virus u skladu s patentnim zahtjevom 14 do 17, naznačen time što je molekula protutijela agonistička.
19. Farmaceutski pripravak, naznačen time što sadrži replikacijski kompetentni onkolitički adenovirus u skladu s bilo kojim od patentnih zahtjeva 1 do 18, kao i razrjeđivač ili nosač.
20. Replikacijski kompetentni adenovirus u skladu s patentnim zahtjevom 1 do 18 ili pripravak u skladu s patentnim zahtjevom 19, naznačeni time što su namijenjeni upotrebi u liječenju.
21. Replikacijski kompetentni adenovirus u skladu s patentnim zahtjevom 1 do 18 ili pripravak u skladu s patentnim zahtjevom 19, naznačeni time što su namijenjeni upotrebi u liječenju raka.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1507419.8A GB201507419D0 (en) | 2015-04-30 | 2015-04-30 | Virus |
| GBGB1516936.0A GB201516936D0 (en) | 2015-09-24 | 2015-09-24 | Virus |
| GBGB1522013.0A GB201522013D0 (en) | 2015-12-14 | 2015-12-14 | Virus |
| PCT/EP2016/059609 WO2016174200A1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
| EP16723043.2A EP3288573B1 (en) | 2015-04-30 | 2016-04-29 | Oncolytic adenovirus encoding a b7 protein |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20200439T1 true HRP20200439T1 (hr) | 2020-06-12 |
Family
ID=56008588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20200439TT HRP20200439T1 (hr) | 2015-04-30 | 2020-03-17 | Onkolitički adenovirus koji kodira protein b7 |
Country Status (31)
| Country | Link |
|---|---|
| US (6) | US11000559B2 (hr) |
| EP (2) | EP3391892A1 (hr) |
| JP (3) | JP6931229B2 (hr) |
| KR (3) | KR20180118249A (hr) |
| CN (2) | CN107690479B (hr) |
| AU (3) | AU2016256582B2 (hr) |
| BR (2) | BR122018004815A2 (hr) |
| CA (1) | CA2984038C (hr) |
| CL (2) | CL2017002731A1 (hr) |
| CO (1) | CO2017010831A2 (hr) |
| CY (1) | CY1122833T1 (hr) |
| DK (1) | DK3288573T3 (hr) |
| EA (1) | EA037611B1 (hr) |
| ES (1) | ES2780366T3 (hr) |
| HK (1) | HK1249009A1 (hr) |
| HR (1) | HRP20200439T1 (hr) |
| HU (1) | HUE048320T2 (hr) |
| IL (3) | IL284375B (hr) |
| LT (1) | LT3288573T (hr) |
| MX (1) | MX2017013684A (hr) |
| MY (1) | MY183703A (hr) |
| PE (2) | PE20181140A1 (hr) |
| PH (1) | PH12017501942A1 (hr) |
| PL (1) | PL3288573T3 (hr) |
| PT (1) | PT3288573T (hr) |
| RS (1) | RS60105B1 (hr) |
| SA (2) | SA520412637B1 (hr) |
| SG (3) | SG10201901482XA (hr) |
| SI (1) | SI3288573T1 (hr) |
| WO (1) | WO2016174200A1 (hr) |
| ZA (1) | ZA201801589B (hr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| AU2014338864C1 (en) | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| US11000559B2 (en) | 2015-04-30 | 2021-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein |
| TW201722985A (zh) | 2015-11-02 | 2017-07-01 | 戊瑞治療有限公司 | Cd80胞外域多肽及其用於癌症治療 |
| MX2018007249A (es) * | 2015-12-17 | 2019-05-16 | Psioxus Therapeutics Ltd | Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este. |
| DK3436591T3 (da) * | 2016-03-31 | 2023-03-20 | The European Molecular Biology Laboratory | Adenovirale coat-protein-afledte transportvehikler |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| EP3507304B1 (en) | 2016-09-02 | 2024-04-03 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with duocars |
| EP3518947B1 (en) * | 2016-09-27 | 2023-07-05 | Sator Therapeutics LLC | Optimized oncolytic viruses and uses thereof |
| WO2018083258A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| WO2018083259A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) * | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| JP2020514324A (ja) * | 2017-02-03 | 2020-05-21 | ユニバーシティ オブ ピッツバーグ −オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション | 腫瘍溶解性ウイルス療法 |
| JP2020517913A (ja) | 2017-04-28 | 2020-06-18 | ファイブ プライム セラピューティクス， インコーポレイテッド | Ｃｄ８０細胞外ドメインポリペプチドによる治療方法 |
| IL270876B1 (en) * | 2017-05-25 | 2024-02-01 | Univ Central Florida Res Found Inc | Novel oncolytic viruses to induce tumor cell killing by natural killer cells |
| CA3064863A1 (en) * | 2017-05-26 | 2018-11-29 | Epicentrx, Inc. | Recombinant adenoviruses carrying transgenes |
| ES2952601T3 (es) | 2017-06-01 | 2023-11-02 | Akamis Bio Ltd | Virus oncolítico y método |
| WO2019147921A1 (en) * | 2018-01-26 | 2019-08-01 | Nantcell, Inc. | Rapid verification of virus particle production for a personalized vaccine |
| GB201801614D0 (en) * | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
| US20210040167A1 (en) * | 2018-03-05 | 2021-02-11 | The Schepens Eye Research Institute, Inc. | Engineered vegf variants for retinal neuroprotection, promotion of axon growth and axon regeneration |
| KR20200136972A (ko) * | 2018-03-30 | 2020-12-08 | 도모키 도도 | 종창 발생 억제형 종양 용해성 바이러스 |
| WO2020052551A1 (en) * | 2018-09-10 | 2020-03-19 | Genesail Biotech (Shanghai) Co. Ltd. | A modified oncolytic virus, composition and use thereof |
| EP3725323A1 (en) * | 2019-04-17 | 2020-10-21 | Targovax Asa | Oncolytic adenoviral vector expressing a member of the b7 family of costimulatory ligands and ada |
| US11434291B2 (en) | 2019-05-14 | 2022-09-06 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| EP3970754A4 (en) * | 2019-05-14 | 2023-08-02 | Oncolys BioPharma, Inc. | METHOD FOR ADMINISTRATION OF AN ONCOLYTIC VIRUS TO TUMOR TISSUE, AND ADMINISTRATION DEVICE |
| GB201909081D0 (en) | 2019-06-25 | 2019-08-07 | Psioxus Therapeutics Ltd | Method |
| GB202102049D0 (en) * | 2021-02-13 | 2021-03-31 | Psioxus Therapeutics Ltd | Viruses |
| WO2023180527A1 (en) * | 2022-03-25 | 2023-09-28 | Universität Zürich | Adenoviral mediated targeting of activated immune cells |
Family Cites Families (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3405241A1 (de) * | 1984-02-15 | 1985-08-29 | Bayer Ag, 5090 Leverkusen | 1-/4-(benzothia- oder -oxazol-2-ylthio- oder -2-yloxy) phenyl/-1,3,5-triazin-2,4,6-(1h,3h,5h)-trione, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
| KR920008907B1 (ko) * | 1989-11-28 | 1992-10-10 | 삼성전자 주식회사 | 파우어 온/오프시 화면 크기 제어회로 |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5846945A (en) | 1993-02-16 | 1998-12-08 | Onyx Pharmaceuticals, Inc. | Cytopathic viruses for therapy and prophylaxis of neoplasia |
| FR2705361B1 (fr) | 1993-05-18 | 1995-08-04 | Centre Nat Rech Scient | Vecteurs viraux et utilisation en thérapie génique. |
| EP0667912B1 (fr) | 1993-07-13 | 2008-07-02 | Centelion | Vecteurs adenoviraux defectifs et utilisation en therapie genique |
| US5631236A (en) | 1993-08-26 | 1997-05-20 | Baylor College Of Medicine | Gene therapy for solid tumors, using a DNA sequence encoding HSV-Tk or VZV-Tk |
| US5830686A (en) | 1994-01-13 | 1998-11-03 | Calydon | Tissue-specific enhancer active in prostate |
| US5677170A (en) | 1994-03-02 | 1997-10-14 | The Johns Hopkins University | In vitro transposition of artificial transposons |
| US5877011A (en) | 1996-11-20 | 1999-03-02 | Genzyme Corporation | Chimeric adenoviral vectors |
| CN1242051A (zh) | 1996-12-31 | 2000-01-19 | 昂尼克斯药物公司 | 用于肿瘤治疗和预防的致细胞病变病毒 |
| ATE374821T1 (de) | 1997-02-20 | 2007-10-15 | Univ Johns Hopkins Med | Mutationen in atp-abhängigen transpositionsproteinen die die zielortspezifität reduzieren |
| US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
| WO2000034494A1 (en) * | 1998-12-09 | 2000-06-15 | The Government Of The United States Of America Represented By The Secretary, Department Of Health And Human Services | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US6291214B1 (en) | 1998-05-11 | 2001-09-18 | Glaxo Wellcome Inc. | System for generating recombinant viruses |
| US20020019051A1 (en) | 1998-05-27 | 2002-02-14 | Monika Lusky | Chimeric adenoviral vectors |
| US20030017138A1 (en) | 1998-07-08 | 2003-01-23 | Menzo Havenga | Chimeric adenoviruses |
| CN1110553C (zh) | 1998-07-15 | 2003-06-04 | 杭州赛狮生物技术开发有限公司 | 基因工程腺病毒及其用途 |
| AU767975B2 (en) * | 1998-09-11 | 2003-11-27 | Genvec, Inc. | Alternatively targeted adenovirus |
| DE60045138D1 (de) | 1999-05-17 | 2010-12-02 | Crucell Holland Bv | Rekombinantes Adenovirus des Ad26-Serotyps |
| EP1181382B1 (en) | 1999-06-01 | 2005-03-23 | The University of Washington | Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration |
| US7396679B2 (en) | 1999-11-15 | 2008-07-08 | Onyx Pharmaceuticals, Inc. | Oncolytic adenovirus |
| CA2398335C (en) * | 2000-01-21 | 2010-12-07 | Biovex Limited | Herpes virus strains |
| US7456009B2 (en) | 2000-03-07 | 2008-11-25 | Merck & Co., Inc. | Adenovirus formulations |
| WO2001092549A2 (en) | 2000-05-31 | 2001-12-06 | Genvec, Inc. | Method and composition for targeting an adenoviral vector |
| ATE449859T1 (de) | 2001-01-04 | 2009-12-15 | Goeran Wadell | Virusvektor zur gentherapie |
| US20050175589A1 (en) * | 2001-07-13 | 2005-08-11 | Btg International Limited | Anti-neoplastic viral agents |
| AR039067A1 (es) | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
| EP1327688A1 (en) | 2002-01-14 | 2003-07-16 | Vereniging Voor Christelijk Wetenschappelijk Onderwijs | Adenoviruses with enhanced lytic potency |
| AU2003206815A2 (en) * | 2002-02-01 | 2003-09-02 | Transgene S.A. | Adenoviral vectors for modulating the cellular activities associated with PODs |
| US7858367B2 (en) | 2002-04-30 | 2010-12-28 | Duke University | Viral vectors and methods for producing and using the same |
| CN1705740B (zh) * | 2002-10-15 | 2013-07-24 | 佩尔·松内·霍尔姆 | 具有反向基因表达的腺病毒及其应用 |
| US20040167088A1 (en) | 2003-02-25 | 2004-08-26 | Genvec, Inc. | Method of using adenoviral vectors with increased persistence in vivo |
| WO2004087930A1 (en) | 2003-03-28 | 2004-10-14 | Saint Louis University | Adenovirus replication-competent vectors expressing trail |
| US20050136035A1 (en) * | 2003-06-03 | 2005-06-23 | Derek Ko | Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site |
| US20050036989A1 (en) | 2003-07-18 | 2005-02-17 | Onyx Pharmaceuticals, Inc. | Subgroup B adenoviral vectors for treating disease |
| US20050186178A1 (en) * | 2003-08-28 | 2005-08-25 | Ennist David L. | Oncolytic adenoviral vectors encoding GM-CSF |
| WO2005086922A2 (en) | 2004-03-10 | 2005-09-22 | Board Of Regents, University Of Texas System | Oncolytic adenovirus armed with therapeutic genes |
| US20080292592A1 (en) | 2004-04-30 | 2008-11-27 | Sunil Chada | Oncolytic Adenovirus Armed with Therapeutic Genes |
| CA2567094C (en) * | 2004-05-26 | 2014-11-25 | Schering Aktiengesellschaft | Chimeric adenoviruses for use in cancer treatment |
| CN100361710C (zh) | 2004-06-07 | 2008-01-16 | 成都康弘生物科技有限公司 | 肿瘤细胞专一表达免疫调节因子gm-csf的溶瘤性腺病毒重组体的构建及其应用 |
| US20060292682A1 (en) * | 2004-07-22 | 2006-12-28 | Hawkins Lynda K | Addition of transgenes into adenoviral vectors |
| CN101068933A (zh) * | 2004-08-25 | 2007-11-07 | 细胞基因系统有限公司 | 用于肿瘤细胞增强转导的纤维修饰的腺病毒载体 |
| CA2589602A1 (en) * | 2004-09-01 | 2006-04-13 | Genvec, Inc. | Adenoviral vectors able to transduce apcs, potential use in immune response generation |
| EP1819823A2 (en) | 2004-12-01 | 2007-08-22 | Bayer Schering Pharma Aktiengesellschaft | Generation of replication competent viruses for therapeutic use |
| WO2007027860A2 (en) | 2005-08-31 | 2007-03-08 | Genvec, Inc. | Adenoviral vector-based malaria vaccines |
| DE102005055128B4 (de) | 2005-11-15 | 2015-04-02 | Universität Rostock | Viraler Vektor, dessen Verwendung zur Therapie von Leberzellkarzinomen und pharmazeutische Mittel umfassend den Vektor |
| ES2304281B1 (es) | 2006-02-01 | 2009-08-12 | Dnatrix Inc. | Adenovirus oncoliticos para el tratamiento del cancer. |
| WO2008080003A2 (en) | 2006-12-22 | 2008-07-03 | Bayer Schering Pharma Aktiengesellschaft | Generation of oncolytic adenoviruses and uses thereof |
| US20110086005A1 (en) | 2008-05-27 | 2011-04-14 | Oncolytics Biotech Inc. | Modulating interstitial pressure and oncolytic viral delivery and distribution |
| CN101381742A (zh) * | 2008-10-23 | 2009-03-11 | 浙江理工大学 | 晚期启动子靶向性调控溶瘤腺病毒pCN305载体及其构建方法与应用 |
| ES2385251B1 (es) * | 2009-05-06 | 2013-05-06 | Fundació Privada Institut D'investigació Biomèdica De Bellvitge | Adenovirus oncolíticos para el tratamiento del cáncer. |
| EP2486137B1 (en) * | 2009-10-05 | 2018-05-30 | Ya-Fang Mei | Replication-competent ad11p based viral vectors |
| KR101957616B1 (ko) | 2010-08-16 | 2019-03-12 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | 아데노바이러스 조립 방법 |
| AU2011306845C1 (en) | 2010-09-24 | 2015-05-14 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors coding for monoclonal anti - CTLA - 4 antibodies |
| US20130323205A1 (en) * | 2010-09-24 | 2013-12-05 | Oncos Therapeutics Oy | Oncolytic adenoviral vectors and methods and uses related thereto |
| US20140316369A1 (en) | 2011-11-14 | 2014-10-23 | Regenerative Sciences, Llc | Suspended particle delivery systems and methods |
| CN102586327B (zh) | 2012-01-18 | 2013-09-11 | 陕西师范大学 | 一步法构建携带外源基因的d24纤维蛋白修饰的条件复制型腺病毒载体及其应用 |
| JP2016512199A (ja) | 2013-03-05 | 2016-04-25 | ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ | 腫瘍溶解性ウイルス |
| GB201322851D0 (en) | 2013-12-23 | 2014-02-12 | Psioxus Therapeutics Ltd | Method |
| AU2014338864C1 (en) * | 2013-10-25 | 2020-07-16 | Akamis Bio Limited | Oncolytic adenoviruses armed with heterologous genes |
| DK3071697T3 (da) | 2013-11-22 | 2020-01-27 | Dnatrix Inc | Adenovirus der udtrykker immuncelle-stimulatorisk(e) receptor agonist(er) |
| GB201406608D0 (en) | 2014-04-12 | 2014-05-28 | Psioxus Therapeutics Ltd | Virus |
| GB201510197D0 (en) * | 2014-06-12 | 2015-07-29 | Psioxus Therapeutics Ltd | Method of treating ovarian cancer |
| GB201503500D0 (en) | 2015-03-02 | 2015-04-15 | Ucl Business Plc | Cell |
| US11485791B2 (en) | 2015-03-17 | 2022-11-01 | Tilt Biotherapeutics Oy | Oncolytic adenoviruses coding for bi-specific antibodies |
| US11000559B2 (en) | 2015-04-30 | 2021-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding a B7 protein |
| MX2018007249A (es) | 2015-12-17 | 2019-05-16 | Psioxus Therapeutics Ltd | Adenovirus del grupo b que codifica un anticuerpo contra el complejo tcr o fragmento de este. |
| AU2017233072B2 (en) | 2016-03-18 | 2020-12-24 | Nantcell, Inc. | Multimodal vector for dendritic cell infection |
| GB201713765D0 (en) | 2017-08-28 | 2017-10-11 | Psioxus Therapeutics Ltd | Modified adenovirus |
| CA3034517A1 (en) | 2016-08-29 | 2018-03-08 | Psioxus Therapeutics Limited | Adenovirus armed with bispecific t cell activator |
| US20200040059A1 (en) | 2016-10-20 | 2020-02-06 | Alpine Immune Sciences, Inc. | Secretable variant immunomodulatory proteins and engineered cell therapy |
| WO2018083259A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083257A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding transgenes |
| WO2018083258A1 (en) | 2016-11-03 | 2018-05-11 | Psioxus Therapeutics Limited | Oncolytic adenovirus encoding at least three transgenes |
| ES2952601T3 (es) * | 2017-06-01 | 2023-11-02 | Akamis Bio Ltd | Virus oncolítico y método |
| GB201801614D0 (en) | 2018-01-31 | 2018-03-14 | Psioxus Therapeutics Ltd | Formulation |
-
2016
- 2016-04-29 US US15/570,100 patent/US11000559B2/en active Active
- 2016-04-29 CA CA2984038A patent/CA2984038C/en active Active
- 2016-04-29 PE PE2018000519A patent/PE20181140A1/es unknown
- 2016-04-29 CN CN201680024692.0A patent/CN107690479B/zh active Active
- 2016-04-29 BR BR122018004815A patent/BR122018004815A2/pt not_active Application Discontinuation
- 2016-04-29 IL IL284375A patent/IL284375B/en unknown
- 2016-04-29 PE PE2017002327A patent/PE20180241A1/es unknown
- 2016-04-29 LT LTEP16723043.2T patent/LT3288573T/lt unknown
- 2016-04-29 SG SG10201901482XA patent/SG10201901482XA/en unknown
- 2016-04-29 SG SG10201803081TA patent/SG10201803081TA/en unknown
- 2016-04-29 RS RS20200325A patent/RS60105B1/sr unknown
- 2016-04-29 HU HUE16723043A patent/HUE048320T2/hu unknown
- 2016-04-29 SG SG11201708604TA patent/SG11201708604TA/en unknown
- 2016-04-29 EA EA201791971A patent/EA037611B1/ru unknown
- 2016-04-29 KR KR1020187030538A patent/KR20180118249A/ko active Application Filing
- 2016-04-29 SI SI201630679T patent/SI3288573T1/sl unknown
- 2016-04-29 AU AU2016256582A patent/AU2016256582B2/en active Active
- 2016-04-29 BR BR112017023171-9A patent/BR112017023171A2/pt active Search and Examination
- 2016-04-29 PL PL16723043T patent/PL3288573T3/pl unknown
- 2016-04-29 EP EP18159326.0A patent/EP3391892A1/en active Pending
- 2016-04-29 KR KR1020177032425A patent/KR102643574B1/ko active IP Right Grant
- 2016-04-29 MY MYPI2017703967A patent/MY183703A/en unknown
- 2016-04-29 JP JP2017552966A patent/JP6931229B2/ja active Active
- 2016-04-29 EP EP16723043.2A patent/EP3288573B1/en active Active
- 2016-04-29 ES ES16723043T patent/ES2780366T3/es active Active
- 2016-04-29 MX MX2017013684A patent/MX2017013684A/es unknown
- 2016-04-29 DK DK16723043.2T patent/DK3288573T3/da active
- 2016-04-29 WO PCT/EP2016/059609 patent/WO2016174200A1/en active Application Filing
- 2016-04-29 KR KR1020247006825A patent/KR20240032177A/ko not_active Application Discontinuation
- 2016-04-29 CN CN201810213204.1A patent/CN108396015B/zh active Active
- 2016-04-29 PT PT167230432T patent/PT3288573T/pt unknown
- 2016-08-08 US US15/231,422 patent/US10124028B2/en active Active
-
2017
- 2017-05-03 US US15/586,091 patent/US10548929B2/en active Active
- 2017-10-25 PH PH12017501942A patent/PH12017501942A1/en unknown
- 2017-10-25 CO CONC2017/0010831A patent/CO2017010831A2/es unknown
- 2017-10-26 CL CL2017002731A patent/CL2017002731A1/es unknown
- 2017-10-26 IL IL255286A patent/IL255286B/en active IP Right Grant
- 2017-10-30 SA SA520412637A patent/SA520412637B1/ar unknown
- 2017-10-30 SA SA517390260A patent/SA517390260B1/ar unknown
- 2017-10-31 US US15/799,644 patent/US10322152B2/en active Active
-
2018
- 2018-02-28 AU AU2018201446A patent/AU2018201446B2/en active Active
- 2018-03-05 CL CL2018000587A patent/CL2018000587A1/es unknown
- 2018-03-07 ZA ZA201801589A patent/ZA201801589B/en unknown
- 2018-03-08 JP JP2018041788A patent/JP6928380B2/ja active Active
- 2018-03-12 IL IL258044A patent/IL258044B/en unknown
- 2018-06-20 HK HK18107929.1A patent/HK1249009A1/zh unknown
- 2018-09-18 US US16/134,704 patent/US10849945B2/en active Active
-
2020
- 2020-03-17 HR HRP20200439TT patent/HRP20200439T1/hr unknown
- 2020-03-18 CY CY20201100253T patent/CY1122833T1/el unknown
- 2020-08-25 AU AU2020223665A patent/AU2020223665A1/en not_active Abandoned
-
2021
- 2021-04-05 US US17/301,502 patent/US20210338753A1/en not_active Abandoned
- 2021-08-05 JP JP2021129196A patent/JP7162929B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20200439T1 (hr) | Onkolitički adenovirus koji kodira protein b7 | |
| JP2018514199A5 (hr) | ||
| JP2019502379A5 (hr) | ||
| JP2019508017A5 (hr) | ||
| US20210069243A1 (en) | Biologically relevant orthogonal cytokine/receptor pairs | |
| JP2019534036A5 (hr) | ||
| SI3021859T1 (en) | Oncolytic adenoviruses equipped with heterologous genes | |
| JP2018139586A5 (hr) | ||
| IL299249B1 (en) | Genetically modified immune cells that include adapted shrna-microRNA (shrnamir) | |
| Waldmann et al. | Interleukin-2, interleukin-15, and their receptors | |
| Mackall et al. | Harnessing the biology of IL-7 for therapeutic application | |
| CN110872577B (zh) | 修饰的免疫细胞及其应用 | |
| WO2015155370A4 (en) | Group b adenovirus modified in the e4orf4 region | |
| JP2018523485A5 (hr) | ||
| Peter et al. | Oncolytic adenovirus in cancer immunotherapy | |
| JP2018528786A5 (hr) | ||
| JP2015096070A5 (hr) | ||
| CN104177499B (zh) | 一种嵌合抗原受体、编码基因、表达载体及其应用 | |
| JP2017525364A5 (hr) | ||
| Stagg et al. | Granulocyte-macrophage colony-stimulating factor and interleukin-2 fusion cDNA for cancer gene immunotherapy | |
| Cervera-Carrascon et al. | Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system. | |
| RU2018104703A (ru) | Опухолеспецифичное антитело против egfr и его применение | |
| WO2021136538A1 (zh) | 促实体瘤浸润的增强型cart细胞及其制备方法和细胞药物 | |
| JP2017501695A5 (hr) | ||
| JP2005523681A5 (hr) |